REAL SCIENCE. REAL POSSIBILITIES.A modified growth-hormone fragment explored for fat metabolism and weight management, although a meaningful weight-loss benefit has not been established.
The attraction is easy to understand: isolate a growth-hormone fragment associated with fat metabolism without recreating the whole hormone. That hypothesis produced real human trials, but the clinical weight-loss result was disappointing.
These cards show what AOD-9604 is best known for and where the interest comes from. When you want the detail, open Research for the studies or Evidence for a quick view of how strong the support is.
The main reasons this compound attracts attention. The Research and Evidence sections give you the deeper scientific picture.
Laboratory and animal work linked the fragment with lipolysis and reduced fat accumulation.
This provides a plausible mechanism, but a laboratory fat-metabolism signal is not proof of meaningful human fat loss.
Community use focuses on fat loss while trying to preserve training and lean tissue.
The largest controlled obesity study did not find significant weight loss compared with placebo despite diet and exercise support.
AOD-9604 was designed from amino acids 176–191 of human growth hormone with an added N-terminal tyrosine.
Human safety summaries did not show the IGF-1 pattern expected from full growth hormone, but that distinction does not create proven efficacy.
AOD-9604 shows why an appealing mechanism must survive dose-ranging and placebo-controlled testing.
Most identified obesity studies were negative, and development for obesity was terminated after the phase IIb programme.
AOD-9604 reached controlled human dose-ranging studies. That makes the negative phase IIb result essential evidence rather than a footnote to the preclinical mechanism.
Modified 176–191 region without full GH signalling
→Cell and animal fat-metabolism rationale
→Oral and intravenous exposure in hundreds
→No significant weight loss in pivotal phase IIb
AOD-9604 moved from GH-fragment and lipolysis biology into oral and intravenous obesity trials. The decisive lesson is that human exposure was feasible, but the central clinical claim was not confirmed.
The molecule uses the 176–191 region of human growth hormone with an added N-terminal tyrosine.
Cell and animal models support lipolysis and reduced fat-accumulation hypotheses.
The 24-week OPTIONS programme enrolled 536 adults and paired treatment with supervised diet and exercise.
No significant weight-loss advantage was demonstrated, and no human subcutaneous efficacy programme validates today's popular route.
300 adults with obesity
536 enrolled adults with obesity; approximately 502 analysed
Participants across six randomized placebo-controlled studies
Several controlled studies exposed hundreds of people to oral or intravenous AOD-9604.
The pivotal obesity programme failed to demonstrate significant weight loss versus placebo.
Short-to-medium-term trial safety data exist, but injectable community use, immunogenicity and long-term product-specific safety remain uncertain.
Animal and laboratory studies support fat-metabolism and tissue hypotheses.
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Multiple studies and a 24-week phase IIb programme
Largest controlled study did not beat placebo
No validated subcutaneous efficacy or dose conversion
A measured biological response can be valuable evidence without establishing a self-administered protocol or a durable treatment benefit.
Fat loss, body recomposition and a perceived non-growth GH alternative—mapped against a substantial human programme that did not establish obesity efficacy.
Community goals · human trial result · injected-route gapAOD-9604 is explored mainly for fat loss, stubborn body-fat areas and a perceived 'non-growth' alternative to full growth hormone. The large human programme is highly relevant because it tested the central claim and did not confirm a meaningful obesity benefit.
Experiences can reveal recurring goals, perceived changes and practical questions that formal studies may not yet address. They can suggest what deserves investigation, but cannot isolate the effect of one compound from rehabilitation, time or other changes.
Human and preclinical research helps test whether an idea is biologically plausible, whether it appears in people and how confidently the result can be separated from chance, bias or other parts of recovery.
Users commonly pair daily use with a calorie deficit and increased activity, making attribution difficult.
The largest 24-week controlled trial found no significant weight loss versus placebo.
Mouse and adipose research supports a lipolysis hypothesis.
Biologically plausible, but contradicted by the strongest direct obesity trial.
Interest often rests on separating a GH fragment from full growth hormone.
Human safety summaries did not show a typical IGF-1 response, but body-composition efficacy was not established.
Fragment studies report metabolic rather than growth-promoting effects.
A meaningful molecular distinction that does not prove a practical benefit.
Flat subcutaneous amounts are widely repeated because they appear simple and compatible with training routines.
FDA found no human subcutaneous pharmacokinetic or efficacy study in its review.
Animal route data cannot supply human subcutaneous equivalence.
A recognizable community pattern with a major route-validation gap.
AOD-9604 is sometimes added when progress from diet, exercise or another medicine slows.
No controlled trial has tested it as a plateau-breaking add-on to modern obesity treatment.
Mechanistic overlap is not combination evidence.
Community rationale only; review the established plan before adding uncertainty.
Community reports can surface patterns worth exploring. Controlled human research is what tests whether those patterns are reliable, clinically meaningful and attributable toAOD-9604, while the available studies show how far that question has already been answered.
Compare published study protocols with the patterns people discuss in the community. The two are intentionally kept separate so an anecdotal routine is never mistaken for clinical guidance.
The example below reflects recurring subcutaneous community discussion. Human obesity trials used oral or intravenous AOD-9604 and did not validate this route or a fat-loss result.
Anecdotal starting amount
Optional small community-described step
No evidence-based escalation
No validated repeat-cycle interval
OPTIONS tested 0.25–1 mg oral doses for 24 weeks and did not show significant weight loss. Oral milligrams cannot validate injected micrograms.
The source shows what has actually been studied. It does not validate the community example above or turn it into guidance.
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
AOD-9604 has human oral and intravenous dose-ranging data, but no validated subcutaneous fat-loss dose or successful obesity regimen.
Adults with obesity receiving diet and exercise support
Published study structure, shown as data — not a personal dosing schedule.
The trial did not show significant weight loss versus placebo; these amounts are evidence of exposure, not a recommendation.
23 men with obesity
Published study structure, shown as data — not a personal dosing schedule.
No significant weight-loss effect was established in this very small study.
Community protocol summaries commonly describe 250–300 mcg subcutaneously once daily, often without titration.
Short 8–12-week cycles are frequently discussed alongside diet and resistance training.
A 4-week break is sometimes described, but no evidence-based washout, maintenance or repeat-cycle interval exists.
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
AOD-9604 + Nutrition and resistance training
AOD-9604 + Prescribed incretin therapy
AOD-9604 + CJC-1295 / Ipamorelin
AOD-9604's largest controlled programme did not produce significant weight loss despite supervised diet and exercise.
Training, nutrition and indicated obesity medicines have their own evidence; no study proves that AOD-9604 adds to them.
People hope to add a selective fat-metabolism signal to an established body-composition foundation.
Diet and exercise were included in the failed phase IIb programme; added peptide benefit was not demonstrated.Community discussion pairs a speculative lipolysis mechanism with established appetite treatment.
No controlled study establishes extra benefit, dosing or safety for the combination.The pairing is framed as fat metabolism plus broader growth-hormone signalling.
No human combination trial supports synergy; overlapping metabolic and endocrine uncertainty increases monitoring needs.Nutrition, activity, sleep and indicated clinical care should remain visible rather than being credited to the peptide.
A second compound cannot turn an unconfirmed AOD-9604 effect into evidence.
Weight, waist, strength and dietary adherence are more informative together than scale changes alone.
Oral and intravenous studies provide more direct human exposure information than a purely preclinical peptide profile.
Most identified obesity studies failed to show benefit, and development for obesity stopped after the phase IIb programme.
Human subcutaneous pharmacokinetics, immunogenicity, impurity exposure, aggregation and long-term repeat-cycle safety are not established.
The summary above reflects the human or preclinical evidence currently represented on this profile.
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Different delivery routes have different absorption and exposure; the popular injected pattern was not the pivotal trial route.
Unapproved injectable products add contamination, concentration and degradation risks independent of the peptide theory.
When expected benefit is uncertain, injection and product risks carry proportionally more weight.
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
AOD-9604 is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.
